专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06322817B1 Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof 有权
标题翻译：紫杉醇，其衍生物或其类似物包埋在聚合物胶束的纳米颗粒中的制剂，其制备方法及其用途
公开(公告)号：US06322817B1
公开(公告)日：2001-11-27
申请号：US09401927
申请日：1999-09-23
申请人： Amarnath Maitra , Sanjeeb Kumar Sahoo , Prasanta Kumar Ghosh , Anand C. Burman , Rama Mukherjee , Dhiraj Khattar , Mukesh Kumar , Soumendu Paul
发明人： Amarnath Maitra , Sanjeeb Kumar Sahoo , Prasanta Kumar Ghosh , Anand C. Burman , Rama Mukherjee , Dhiraj Khattar , Mukesh Kumar , Soumendu Paul
IPC分类号： A61K4730
CPC分类号： A61K9/5138 , A61K9/1075 , A61K9/5146 , A61K9/5192 , A61K31/337 , Y10S977/906
摘要： This invention relates to pharmaceutical formulations of paclitaxel, its derivatives or analogs entrapped into nanoparticles of co-polymeric micelles, a process for preparing the same and the use thereof.
摘要翻译：本发明涉及包埋在共聚合胶束纳米颗粒中的紫杉醇，其衍生物或类似物的药物制剂，其制备方法及其用途。

2. 发明授权

US08048434B2 Vaccine adjuvants 有权
标题翻译：疫苗佐剂
公开(公告)号：US08048434B2
公开(公告)日：2011-11-01
申请号：US10583731
申请日：2006-04-21
申请人： Bakulesh Mafatlal Khamar , Rajiv Indravadan Modi , Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Nirav Desai
发明人： Bakulesh Mafatlal Khamar , Rajiv Indravadan Modi , Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Nirav Desai
IPC分类号： A61K39/04 , A61K39/02 , A61K39/00
CPC分类号： A61K39/39 , A61K2039/55594
摘要： The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses.Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.
摘要翻译：本发明涉及一种新型佐剂分枝杆菌及其组分和含佐剂的组合物，其含有具有药学上可接受的载体的抗原及其用途。当向哺乳动物施用抗原时，分枝杆菌和/或其成分导致抗原的增强的免疫原性。增强的免疫原性表现为体液应答以及细胞介导的免疫。在各种哺乳动物的多种抗原中观察到佐剂效果，不管在施用分枝杆菌和含抗原组合物时其免疫状态如何。例如免疫原始或预免疫状态。

3. 发明申请

US20120328574A1 P38 INHIBITORS 审中-公开
标题翻译： P38抑制剂
公开(公告)号：US20120328574A1
公开(公告)日：2012-12-27
申请号：US13535917
申请日：2012-06-28
申请人： Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Devesh Bhardwaj , Nirav Desai , Bakulesh Mafatlal Khamar
发明人： Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Devesh Bhardwaj , Nirav Desai , Bakulesh Mafatlal Khamar
IPC分类号： A61K35/74 , A61P37/02 , A61P19/08 , A61P9/10 , A61P37/08 , A61P25/28 , A61P35/00 , A61P29/00
CPC分类号： A61K35/74
摘要： The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition The inhibition is found to last more than 28 days. It is also found to induce inhibition of TNF-α it suppresses cytokines in a pattern identical to Glucocorticoids. In transforms cells it also induces apoptosis. P38 mediated conditions include inflammation, cell differentiation, cell proliferation, cell inhibition, cell cycle regulation, anti-inflammatory reactions, immune modulation, vascularization, response to external stimuli and angiogenesis. The use of Mycobacterium w (Mw) and/or constituents of Mycobacterium w for inhibition of p38 protein kinase i.e. (i) to induce apoptosis in transformed cells (ii) for inhibition of TNF-α (iii) for inhibition of cytokines.
摘要翻译：本发明涉及新颖的p38MAPK抑制剂，其涉及在药学上可接受的载体中的分枝杆菌和/或其成分及其用途。当对哺乳动物施用时，分枝杆菌w和/或其成分导致p38抑制。发现抑制持续超过28天。还发现诱导TNF-α的抑制，其以与糖皮质激素相同的模式抑制细胞因子。在转化细胞时，它也诱导细胞凋亡。 P38介导的病症包括炎症，细胞分化，细胞增殖，细胞抑制，细胞周期调节，抗炎反应，免疫调节，血管化，对外部刺激的反应和血管生成。使用分枝杆菌w（Mw）和/或分枝杆菌w的成分抑制p38蛋白激酶，即（i）诱导转化细胞凋亡（ii）抑制TNF-α（iii）用于抑制细胞因子。

4. 发明申请

US20100104536A1 P38 INHIBITORS 审中-公开
标题翻译： P38抑制剂
公开(公告)号：US20100104536A1
公开(公告)日：2010-04-29
申请号：US12532100
申请日：2008-03-18
申请人： Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Devesh Bhardwaj , Nirav Desai , Bakulesh Mafatlal Khamar
发明人： Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Devesh Bhardwaj , Nirav Desai , Bakulesh Mafatlal Khamar
IPC分类号： A61K35/74 , C12N9/99 , C12N5/02 , C07K14/52
CPC分类号： A61K35/74
摘要： The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition The inhibition is found to last more than 28 days. It is also found to induce inhibition of TNF-alfa. it suppresses cytokines in a pattern identical to Glucocorticoids. In transforms cells it also induces apoptosis. P38 mediated conditions include inflammation, cell differentiation, cell proliferation, cell inhibition, cell cycle regulation, anti-inflammatory reactions, immune modulation, vascularization, response to external stimuli and angiogenesis. The use of Mycobacterium w (Mw) and/or constituents of Mycobacterium w for inhibition of p38 protein kinase i.e. (i) to induce apoptosis in transformed cells (ii) for inhibition of TNF-alfa (iii) for inhibition of cytokines.
摘要翻译：本发明涉及新颖的p38MAPK抑制剂，其涉及在药学上可接受的载体中的分枝杆菌和/或其成分及其用途。当对哺乳动物施用时，分枝杆菌w和/或其成分导致p38抑制。发现抑制持续超过28天。还发现诱导TNF-α的抑制。它以与糖皮质激素相似的模式抑制细胞因子。在转化细胞时，它也诱导细胞凋亡。 P38介导的病症包括炎症，细胞分化，细胞增殖，细胞抑制，细胞周期调节，抗炎反应，免疫调节，血管化，对外部刺激的反应和血管生成。使用分枝杆菌w（Mw）和/或组织分枝杆菌w来抑制p38蛋白激酶，即（i）诱导转化细胞凋亡（ii）抑制TNF-α（iii）抑制细胞因子。

5. 发明申请

US20080131458A1 Vaccine Adjuvants 有权
标题翻译：疫苗佐剂
公开(公告)号：US20080131458A1
公开(公告)日：2008-06-05
申请号：US10583731
申请日：2006-04-21
申请人： Bakulesh Mafatlal Khamar , Rajiv Indravadan Modi , Indravadan Arnbalal Modi , Prasanta Kumar Ghosh , Nirav Desai
发明人： Bakulesh Mafatlal Khamar , Rajiv Indravadan Modi , Indravadan Arnbalal Modi , Prasanta Kumar Ghosh , Nirav Desai
IPC分类号： A61K39/12 , A61K39/04 , A61K45/00 , A61K39/00 , C12M1/20 , A61K39/35 , A61K39/02
CPC分类号： A61K39/39 , A61K2039/55594
摘要： The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses.Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.
摘要翻译：本发明涉及一种新型佐剂分枝杆菌及其组分和含佐剂的组合物，其含有具有药学上可接受的载体的抗原及其用途。当向哺乳动物施用抗原时，分枝杆菌和/或其成分导致抗原的增强的免疫原性。增强的免疫原性表现为体液应答以及细胞介导的免疫。在各种哺乳动物的多种抗原中观察到佐剂效果，不管在施用分枝杆菌和含抗原组合物时其免疫状态如何。例如免疫天真或预免疫状态。

6. 发明授权

US08277778B2 Vaccine adjuvants 失效
标题翻译：疫苗佐剂
公开(公告)号：US08277778B2
公开(公告)日：2012-10-02
申请号：US13242909
申请日：2011-09-23
申请人： Bakulesh Mafatlal Khamar , Rajiv Indravadan Modi , Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Nirav Desai
发明人： Bakulesh Mafatlal Khamar , Rajiv Indravadan Modi , Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Nirav Desai
IPC分类号： A61K49/00 , A61K39/04 , G01N33/53
CPC分类号： A61K39/39 , A61K2039/55594
摘要： The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen(s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.
摘要翻译：本发明涉及一种新型佐剂分枝杆菌及其组分和含佐剂的组合物，其含有具有药学上可接受的载体的抗原及其用途。当向哺乳动物施用抗原时，分枝杆菌和/或其成分导致抗原的增强的免疫原性。增强的免疫原性表现为体液应答以及细胞介导的免疫。在各种哺乳动物的多种抗原中观察到佐剂效果，不管在施用分枝杆菌和含抗原组合物时其免疫状态如何。例如免疫原始或预免疫状态。

7. 发明申请

US20120014985A1 Vaccine Adjuvants 失效
标题翻译：疫苗佐剂
公开(公告)号：US20120014985A1
公开(公告)日：2012-01-19
申请号：US13242909
申请日：2011-09-23
申请人： BAKULESH MAFATLAL KHAMAR , Rajiv Indravadan Modi , Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Nirav Desai
发明人： BAKULESH MAFATLAL KHAMAR , Rajiv Indravadan Modi , Indravadan Ambalal Modi , Prasanta Kumar Ghosh , Nirav Desai
IPC分类号： A61K39/385 , A61K39/04 , A61P37/00 , A61K39/12
CPC分类号： A61K39/39 , A61K2039/55594
摘要： The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.
摘要翻译：本发明涉及一种新型佐剂分枝杆菌及其组分和含佐剂的组合物，其含有具有药学上可接受的载体的抗原及其用途。当向哺乳动物施用抗原时，分枝杆菌和/或其成分导致抗原的增强的免疫原性。增强的免疫原性表现为体液应答以及细胞介导的免疫。在各种哺乳动物的多种抗原中观察到佐剂效果，不管在施用分枝杆菌和含抗原组合物时其免疫状态如何。例如免疫天真或预免疫状态。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式